Aptamer therapeutics in Oncology can be configured in various ways:

  • Antagonist of protein-protein or receptor-ligand interactions

  • Aptamer–drug conjugates (ApDCs)

  • Aptamer-siRNA conjugates

  • Aptamer bi-specifics

Her3 Inhibitor Aptamer’s Intrinsic Anti-tumor Activity Can Be Augmented And Potency Improved By Conjugation to DM1

Aptamer (GRX1461) inhibits BXPC3 tumor growth in a dose dependent manner

  • Highest dose is equivalent to gemcitabine

Aptamer toxin conjugate (GRX1462) has improved potency

  • Highest dose completely inhibits tumor growth


© 2022 Guardian Therapeutics. All rights reserved.

Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:

Business Development Inquiries: businessdevelopment@guardian-rx.com